Neutrophils constitute the main infiltrating cell type in Behçet’s syndrome lesions. By producing excessive levels of reactive oxygen species and releasing neutrophil extracellular traps, neutrophils ...

The small-molecule phosphodiesterase 4 inhibitor apremilast modulates cytokines that are up-regulated in Behçet’s syndrome. In a phase 2 trial involving patients with Behçet’s syndrome, apremilast ...

Hatemi, one of the two co-convenors of the EULAR task force behind the revised recommendations, said there had been changes not just to the content but also to the wording of the recommendations to ...

Both infliximab and adalimumab are safe and effective in achieving remission in patients with severe mucocutaneous Behçet syndrome, with adalimumab demonstrating a quicker response time; both drugs ...

Behcet's syndrome (BS) is a rare disorder of unknown etiology. Also known as Adamantiades-Behcet's syndrome, it is a multisystem complication of the inflammatory system. It is a combination of ...

An analysis of human genetic and biomarker data found that tuberculosis was a risk factor for Behçet disease, a noninfectious uveitis condition. An analysis of human genetic and biomarker data ...

The EULAR recommendations for the management of Behçet’s syndrome were first published in 2008, and updated in 2018. Since that time, new evidence has become available, including trials of biologic ...